미국 - 영어 - NLM (National Library of Medicine)

twi pharmaceuticals, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 125 mg in 5 ml - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cep

미국 - 영어 - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptibile strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data estabilishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 275 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: sunset yellow fcf; lactose monohydrate; iron oxide yellow; titanium dioxide; magnesium stearate; gelatin; brilliant blue fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections - caused by s. pneumoniae and group a b-haemolytic streptococci. (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis - caused by streptococci, s. pneumoniae and s aureus (methicillin sensitive only). otitis media - due to s. pneumoniae, staphylococci; skin and skin structure infections - caused by staphylococci and/or streptococci; genitourinary tract infections, including acute prostatitis - caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note:- appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

미국 - 영어 - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cephalexin anhydrous (unii: 5sff1w6677) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg

오스트레일리아 - 영어 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 300.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | osteomyelitis | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | staphylococcus spp. | tonsillitis

미국 - 영어 - NLM (National Library of Medicine)

stat rx usa llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin 125 mg in 5 ml - cephalexin for oral suspension, usp is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin for oral suspension, usp is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections

미국 - 영어 - NLM (National Library of Medicine)

rebel distributors corp - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules, usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin capsules, usp are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, usp in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus, treptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus yogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis   genitourinary tract infections, including acute

미국 - 영어 - NLM (National Library of Medicine)

state of florida doh central pharmacy - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules, usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:   respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.   cephalexin capsules, usp are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, usp in the subsequent prevention of rheumatic fever are not available at present.)   otitis media due to streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus, streptococcus pyogenes , and moraxella catarrhalis   skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes   bone infections caused by staphylococcus aureus an

미국 - 영어 - NLM (National Library of Medicine)

blenheim pharmacal, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis skin and skin structure infections caused by staphylococci and/or streptococci bone infections caused by staphylococci and/or p. mirabilis genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae note - culture and susceptibility tests should be initiated prior to and during

미국 - 영어 - NLM (National Library of Medicine)

strategic pharmaceutical solutions, inc. dba vetsource - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis skin and skin structure infections caused by staphylococci and/or streptococci bone infections caused by staphylococci and/or p. mirabilis genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae note - culture and susceptibility tests should be initiated prior to and during